Protection against murine osteoarthritis by inhibition of the 26S proteasome and lysine-48 linked ubiquitination

Annals of the Rheumatic Diseases

Volumn 74, Issue 8, 2015, Pages 1580-1587

  Radwan, Marta ^a,b   Wilkinson, David J ^a   Hui, Wang ^a   Destrument, Auriane P M ^a   Charlton, Sarah H ^a   Barter, Matt J ^a   Gibson, Beth ^a   Coulombe, Josée ^c   Gray, Douglas A ^a,c   Rowan, Andrew D ^a   Young, David A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COLLAGENASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LYSINE; PROTEASOME; UBIQUITIN; ATP DEPENDENT 26S PROTEASE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; LEUPEPTIN; MMP13 PROTEIN, MOUSE; SIGNAL PEPTIDE; ZINC FINGER PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOVINE; CARTILAGE CELL; CARTILAGE DEGENERATION; CHONDROLYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMUR CONDYLE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNEE MENISCUS; KNEE OSTEOARTHRITIS; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UBIQUITINATION; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOPRECIPITATION; METABOLISM; OSTEOARTHRITIS; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUPEPTINS; LYSINE; MATRIX METALLOPROTEINASE 13; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOARTHRITIS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITINATION; ZINC FINGERS;

EID: 84940377826     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204962     Document Type: Article

References (41)

1. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006;20:3-25.
2. Loeser R. Molecular mechanisms of cartilage destruction in osteoarthritis. Biochem J 2008;8:303-6.
3. Muir H. The chondrocyte, architect of cartilage. Biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Bioessays 1995;17:1039-48.
4. Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005;434:644-8.
5. Chitra S, Nalini G, Rajasekhar G. The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases. Int J Rheum Dis 2012;15:249-60.
6. Li W, Ye Y. Polyubiquitin chains: functions, structures, and mechanisms. Cell Mol Life Sci 2008;65:2397-406.
7. Zhang Q, Hui W, Litherland GJ, et al. Differential Toll-like receptor-dependent collagenase expression in chondrocytes. Ann Rheum Dis 2008;67:1633-41.
8. Radwan M, Gavriilidis C, Robinson JH, et al. Matrix metalloproteinase 13 expression in response to double-stranded RNA in human chondrocytes. Arthritis Rheum 2013;65:1290-301.
9. Lopitz-Otsoa F, Rodriguez-Suarez E, Aillet F, et al. Integrative analysis of the ubiquitin proteome isolated using Tandem Ubiquitin Binding Entities (TUBEs). J Proteomics 2012;75:2998-3014.
10. Ishihama Y, Oda Y, Tabata T, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 2005;4:1265-72.
11. Barter MJ, Pybus L, Litherland GJ, et al. HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix Biol 2010;29:602-12.
12. Barter MJ, Hui W, Lakey RL, et al. Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation. Ann Rheum Dis 2010;69:2189-98.
13. Hui W, Cawston TE. In vitro model of cartilage degradation. Methods Mol Biol 2010;622:341-8.
14. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage 2007;15:1061-9.
15. Ahmed AS, Li J, Ahmed M, et al. Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132. Arthritis Rheum 2010;62:2160-9.
16. Glasson SS, Chambers MG, Van Den Berg WB, et al. The OARSI histopathology initiative-recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 2010;18(Suppl 3):S17-23.
17. Culley KL, Hui W, Barter MJ, et al. Class I histone deacetylase inhibition modulates metalloproteinase expression and blocks cytokine-induced cartilage degradation. Arthritis Rheum 2013;65:1822-30.
18. Zhang M, Thurig S, Tsirigotis M, et al. Effects of mutant ubiquitin on ts1 retrovirus-mediated neuropathology. J Virol 2003;77:7193-201.
19. Tsirigotis M, Thurig S, Dube M, et al. Analysis of ubiquitination in vivo using a transgenic mouse model. Biotechniques 2001;31:120-6, 8, 30.
20. Iwai K. Diverse ubiquitin signaling in NF-kappaB activation. Trends Cell Biol 2012;22:355-64.
21. Buss H, Dorrie A, Schmitz ML, et al. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1(TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem 2004;279:55633-43.
22. Xu J, Wang S, Zhang M, et al. Tyrosine nitration of PA700 links proteasome activation to endothelial dysfunction in mouse models with cardiovascular risk factors. PLoS ONE 2012;7:e29649.
23. Sanada T, Takaesu G, Mashima R, et al. FLN29 deficiency reveals its negative regulatory role in the Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like helicase signaling pathway. J Biol Chem 2008;283:33858-64.
24. Yannaki E, Papadopoulou A, Athanasiou E, et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum 2010;62:3277-88.
25. Quan R, Huang Z, Yue Z, et al. Effects of a proteasome inhibitor on the NF-kappaB signalling pathway in experimental osteoarthritis. Scand J Rheumatol 2013;42:400-7.
26. Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773-85.
27. Harhaj EW, Dixit VM. Regulation of NF-kappaB by deubiquitinases. Immunol Rev 2012;246:107-24.
28. Yao TP. The role of ubiquitin in autophagy-dependent protein aggregate processing. Genes Cancer 2010;1:779-86.
29. Carames B, Taniguchi N, Otsuki S, et al. Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis. Arthritis Rheum 2010;62:791-801.
30. Kimura Y, Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J Biochem 2010;147:793-8.
31. Chen LX, Lin L, Wang HJ, et al. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartilage 2008;16:174-84.
32. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011;23:471-8.
33. Nam J, Aguda BD, Rath B, et al. Biomechanical thresholds regulate inflammation through the NF-kappaB pathway: experiments and modeling. PLoS ONE 2009;4:e5262.
34. Burleigh A, Chanalaris A, Gardiner MD, et al. Joint immobilization prevents murine osteoarthritis and reveals the highly mechanosensitive nature of protease expression in vivo. Arthritis Rheum 2012;64:2278-88.
35. van der Kraan PM, Goumans MJ, Blaney Davidson E, et al. Age-dependent alteration of TGF-beta signalling in osteoarthritis. Cell Tissue Res 2012;347:257-65.
36. Staines KA, Macrae VE, Farquharson C. Cartilage development and degeneration: a Wnt Wnt situation. Cell Biochem Funct 2012;30:633-42.
37. Kim W, Bennett EJ, Huttlin EL, et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 2011;44:325-40.
38. Wagner SA, Beli P, Weinert BT, et al. Proteomic analyses reveal divergent ubiquitylation site patterns in murine tissues. Mol Cell Proteomics 2012;11:1578-85.
39. Hornbeck PV, Kornhauser JM, Tkachev S, et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 2012;40:D261-70.
40. Mashima R, Saeki K, Aki D, et al. FLN29, a novel interferon- and LPS-inducible gene acting as a negative regulator of toll-like receptor signaling. J Biol Chem 2005;280:41289-97.
41. Frank S, Peters MA, Wehmeyer C, et al. Regulation of matrixmetalloproteinase-3 and matrixmetalloproteinase-13 by SUMO-2/3 through the transcription factor NF-kappaB. Ann Rheum Dis 2013;72:1874-81.